Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moderna TX booster safety and immunogenicity study
PACTR202212801139469Phase 2Unknown
- Sponsor
- Moderna Inc
- Start
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Moderna Inc. Primary endpoint: Safety and reactogenicity. Status: unknown.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202212801139469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202212801139469.